• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Spontaneous regression of cutaneous squamous cell carcinoma and in-transit metastases following cessation of ruxolitinib.

作者信息

Paterson Luke, Paterson Benjamin, Surendra Vishak, Powell Christopher

机构信息

Te Whatu Ora Health, Te Tai Tokerau, Whangārei, New Zealand.

Wellington Blood and Cancer Centre, New Zealand.

出版信息

JAAD Case Rep. 2024 Jan 28;45:106-109. doi: 10.1016/j.jdcr.2024.01.016. eCollection 2024 Mar.

DOI:10.1016/j.jdcr.2024.01.016
PMID:38434599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10907384/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/95c79a8f8294/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/cdfb1897480d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/0c979c1cf5b1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/a775487fd99b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/95c79a8f8294/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/cdfb1897480d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/0c979c1cf5b1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/a775487fd99b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e1d/10907384/95c79a8f8294/gr4.jpg

相似文献

1
Spontaneous regression of cutaneous squamous cell carcinoma and in-transit metastases following cessation of ruxolitinib.鲁索替尼停药后皮肤鳞状细胞癌及皮肤转移灶的自发消退
JAAD Case Rep. 2024 Jan 28;45:106-109. doi: 10.1016/j.jdcr.2024.01.016. eCollection 2024 Mar.
2
In-transit metastasis from primary cutaneous squamous cell carcinoma in a nonimmunosuppressed patient.非免疫抑制患者原发性皮肤鳞状细胞癌的转移途中转移
J Cutan Med Surg. 2015 Mar-Apr;19(2):167-70. doi: 10.2310/7750.2014.14047. Epub 2015 Mar 11.
3
In-transit metastasis of cutaneous squamous cell carcinoma: report of two cases.皮肤鳞状细胞癌的转移：两例报告。
Acta Dermatovenerol Alp Pannonica Adriat. 2022 Jun;31(2):75-77.
4
In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients.器官移植受者和非免疫抑制患者原发性皮肤鳞状细胞癌的转运途中转移：21例患者的临床特征、治疗及结局
Dermatol Surg. 2004 Apr;30(4 Pt 2):651-5. doi: 10.1111/j.1524-4725.2004.30151.x.
5
In-Transit Metastasis of Cutaneous Squamous Cell Carcinoma With Lymphovascular Invasion in an Immunocompetent Patient.免疫功能正常患者皮肤鳞状细胞癌伴淋巴管侵犯的转运途中转移
Cureus. 2022 Jan 13;14(1):e21204. doi: 10.7759/cureus.21204. eCollection 2022 Jan.
6
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.使用鲁索替尼治疗的患者中快速生长且侵袭性强的皮肤鳞状细胞癌
Ann Dermatol. 2019 Apr;31(2):204-208. doi: 10.5021/ad.2019.31.2.204. Epub 2019 Feb 28.
7
Extraordinarily aggressive cutaneous sarcomatoid squamous cell carcinoma of the face: a case report.面部侵袭性极强的皮肤肉瘤样鳞状细胞癌：一例报告
Arch Craniofac Surg. 2022 Apr;23(2):77-82. doi: 10.7181/acfs.2022.00059. Epub 2022 Apr 20.
8
Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy.抗 PD-1 免疫疗法成功治疗转移期皮肤鳞状细胞癌。
World J Surg Oncol. 2023 Sep 15;21(1):291. doi: 10.1186/s12957-023-03179-3.
9
Aggressive locoregional behavior of cutaneous squamous cell carcinoma during ruxolitinib use.在使用鲁索替尼期间皮肤鳞状细胞癌的侵袭性局部行为。
Ann Dermatol Venereol. 2021 Jun;148(2):140-141. doi: 10.1016/j.annder.2020.10.018. Epub 2021 Jan 19.
10
Cutaneous Metastasis From Tonsillar Squamous Cell Carcinoma: Report and Review of the Literature.扁桃体鳞状细胞癌的皮肤转移：病例报告及文献综述
Cureus. 2017 Mar 28;9(3):e1122. doi: 10.7759/cureus.1122.

引用本文的文献

1
Case report: Partial regression of metastatic squamous cell carcinoma with altered azathioprine dosage after long-term use in renal transplant patient.病例报告：肾移植患者长期使用硫唑嘌呤改变剂量后，转移性鳞状细胞癌部分消退。
Front Immunol. 2024 Oct 31;15:1474663. doi: 10.3389/fimmu.2024.1474663. eCollection 2024.

本文引用的文献

1
CD4 T cell-induced inflammatory cell death controls immune-evasive tumours.CD4 T 细胞诱导的炎症细胞死亡控制免疫逃避肿瘤。
Nature. 2023 Jun;618(7967):1033-1040. doi: 10.1038/s41586-023-06199-x. Epub 2023 Jun 14.
2
Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data.芦可替尼治疗的骨髓纤维化患者发生的医源性卡波西肉瘤：病例报告、文献综述及法国药物警戒数据
Am J Hematol. 2022 Jan 1;97(1):E31-E34. doi: 10.1002/ajh.26398. Epub 2021 Nov 9.
3
A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
一项关于芦可替尼与真性红细胞增多症和骨髓纤维化患者非黑色素瘤皮肤癌相关性的10年回顾性队列研究。
J Am Acad Dermatol. 2022 Feb;86(2):339-344. doi: 10.1016/j.jaad.2021.10.004. Epub 2021 Oct 11.
4
The spontaneous remission of cancer: Current insights and therapeutic significance.癌症的自发缓解：当前见解与治疗意义。
Transl Oncol. 2021 Sep;14(9):101166. doi: 10.1016/j.tranon.2021.101166. Epub 2021 Jul 6.
5
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.使用鲁索替尼治疗的患者中快速生长且侵袭性强的皮肤鳞状细胞癌
Ann Dermatol. 2019 Apr;31(2):204-208. doi: 10.5021/ad.2019.31.2.204. Epub 2019 Feb 28.
6
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.芦可替尼治疗糖皮质激素难治性急性移植物抗宿主病。
N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22.
7
Development of Aggressive Squamous Cell Carcinoma With Perineural Invasion During Ruxolitinib Treatment.芦可替尼治疗期间发生伴神经周围侵犯的侵袭性鳞状细胞癌
Dermatol Surg. 2019 May;45(5):734-736. doi: 10.1097/DSS.0000000000001626.
8
JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.JAK1/2 抑制会损害体外和骨髓增殖性肿瘤患者的 T 细胞功能。
Br J Haematol. 2015 Jun;169(6):824-33. doi: 10.1111/bjh.13373. Epub 2015 Mar 30.
9
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.COMFORT-II 研究的 3 年疗效、安全性和生存结果，该研究是一项比较芦可替尼与骨髓纤维化最佳可用疗法的 3 期研究。
Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.
10
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.JAK 抑制剂芦可替尼在体外和体内均可损害树突状细胞功能。
Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14.